纯红细胞再生障碍性贫血的诊断与治疗进展
Progress in Diagnosis and Treatment of Pure Red Cell Aplastic Anemia
DOI: 10.12677/ACM.2024.141290, PDF,   
作者: 王兰兰, 郝建萍*：新疆医科大学第一附属医院血液科，新疆 乌鲁木齐
关键词: 纯红细胞再生障碍性贫血；克隆造血；环孢素；西罗莫司；Pure Red Cell Aplasia； Clonal Hematopoiesis； Cyclosporine； Sirolimus
摘要: 纯红细胞发育不全(PRCA)是一种罕见的血液学综合征，其特征是孤立的正红细胞贫血伴严重网状红细胞减少症，并以骨髓中红细胞前体缺失或几乎缺失为特征。PRCA可能是一种原发性自身免疫性或克隆性髓系或淋巴系疾病，但也可能继发于其他自身免疫疾病、感染、肿瘤或药物。PRCA导致的血细胞异常仅限于红细胞谱系，通常不影响其他细胞系。从PRCA研究中获得的见解有助于阐明对红细胞生成调控的理解。这篇综述总结了PRCA的分类、诊断和治疗方法。
Abstract: Pure red cell aplasia (PRCA) is a rare hematologic syndrome, characterized by an isolated normo-cytic anemia with severe reticulocytopenia, and defined by absence or near absence of erythroid precursors in the bone marrow. PRCA may be a primary autoimmune or clonal myeloid or lymphoid disorder, but may also be secondary to other disorders of autoimmunity, to infections, to neoplasms, or to drugs. Insights from the study of PRCA have helped illuminate the understanding of the regu-lation of erythropoiesis. This review summarizes the classification, diagnosis, and treatment of PRCA.
文章引用：王兰兰, 郝建萍. 纯红细胞再生障碍性贫血的诊断与治疗进展[J]. 临床医学进展, 2024, 14(1): 2058-2063. https://doi.org/10.12677/ACM.2024.141290

参考文献

[1] Means, R.T. (2016) Pure Red Cell Aplasia. Blood, 128, 2504-2509. [Google Scholar] [CrossRef] [PubMed]
[2] Da, Costa, L.M., Leblanc, T.M. and Narla, M. (2020) Dia-mond-Blackfan Anemia. Blood, 136, 1262-1273. [Google Scholar] [CrossRef] [PubMed]
[3] Willig, T.N., Niemeyer, C.M., et al. (1999) Identification of New Prognosis Factors from the Clinical and Epidemiologic Analysis of a Registry of 229 Diamond-Blackfan Anemia Pa-tients. Pediatric Research, 46, 553-561. [Google Scholar] [CrossRef] [PubMed]
[4] Vlachos, A., Ball, S., et al. (2008) Diagnosing and Treating Diamond Blackfan Anaemia: Results of an International Clinical Consensus Conference. British Journal of Haematology, 142, 859-876. [Google Scholar] [CrossRef] [PubMed]
[5] Dessypris, E.N., Krantz, S.B., Roloff, J.S. and Lukens, J.N. (1982) Mode of Action of the IgG Inhibitor of Erythropoiesis in Transient Erythroblastopenia of Childhood. Blood, 59, 114-123. [Google Scholar] [CrossRef] 
[6] Gagne, K.E., Ghazvinian, R., Yuan, D., et al. (2014) Pearson Marrow Pancreas Syndrome in Patients Suspected to Have Diamond-Blackfan Anemia. Blood, 124, 437-440. [Google Scholar] [CrossRef] [PubMed]
[7] Narla, A., Vlachos, A. and Nathan, D.G. (2011) Diamond Blackfan Anemia Treatment: Past, Present, and Future. Seminars in Hematology, 48, 117-123. [Google Scholar] [CrossRef] [PubMed]
[8] Ball, S.E., McGuckin, C.P., Jenkins, G. and Gor-don-Smith, E.C. (1996) Diamond-Blackfan Anaemia in the U.K.: Analysis of 80 Cases from a 20-Year Birth Cohort. British Journal of Haematology, 94, 645-653. [Google Scholar] [CrossRef] [PubMed]
[9] Wang, H., Niu, H., Zhang, T., Xing, L., Shao, Z. and Fu, R. (2021) Low-and Intermediaterisk Myelodysplastic Syndrome with Pure Red Cell Aplasia. Hematology, 26, 444-446. [Google Scholar] [CrossRef] [PubMed]
[10] Hirokawa, M., Sawada, K., Fujishima, N., et al. (2015) Long-Term Outcome of Patients with Acquired Chronic Pure Red Cell Aplasia (PRCA) Following Immunosup-pressive Therapy: A Final Report of the Nationwide Cohort Study in 2004/2006 by the Japan PRCA Collaborative Study Group. British Journal of Haematology, 169, 879-886. [Google Scholar] [CrossRef] [PubMed]
[11] Abkowitz, J.L., Kadin, M.E., Powell, J.S. and Adamson, J.W. (1986) Pure Red Cell Aplasia: Lymphocyte Inhibition of Erythropoiesis. British Journal of Haematology, 63, 59-67. [Google Scholar] [CrossRef] [PubMed]
[12] Fujishima, N., Hirokawa, M., Fujishima, M., et al. (2006) Oligoclonal T Cell Expansion in Blood But Not in the Thymus from a Patient with Thymoma-Associated Pure Red Cell Aplasia. Haematologica, 91, ECR47.
[13] Hirokawa, M., Sawada, K., Fujishima, N., et al. (2008) Long-Term Response and Outcome Following Immunosuppressive Therapy in Thymoma-Associated Pure Red Cell Aplasia: A Na-tionwide Cohort Study in Japan by the PRCA Collaborative Study Group. Haematologica, 93, 27-33. [Google Scholar] [CrossRef] [PubMed]
[14] Ishida, F., Matsuda, K., Sekiguchi, N., et al. (2014) STAT3 Gene Mutations and Their Association with Pure Red Cell Aplasia in Large Granular Lymphocyte Leukemia. Cancer Science, 105, 342-346. [Google Scholar] [CrossRef] [PubMed]
[15] Frickhofen, N., Chen, Z.J., Young, N.S., Cohen, B.J., Heimpel, H. and Abkowitz, J.L. (1994) Parvovirus B19 as a Cause of Acquired Chronic Pure Red Cell Aplasia. British Journal of Haematology, 87, 818-824. [Google Scholar] [CrossRef] [PubMed]
[16] Tanaka, Y., Matsui, K., Yamashita, K., Matsuda, K., Shinohara, K. and Matsutani, A. (2006) T-Gamma Delta Large Granular Lymphocyte Leukemia Preceded by Pure Red Cell Aplasia and Complicated with Hemophagocytic Syndrome Caused by Epstein-Barr Virus Infection. Internal Medi-cine, 45, 631-635. [Google Scholar] [CrossRef] [PubMed]
[17] Dessypris, E.N., Redline, S., Harris, J.W. and Krantz, S.B. (1985) Diphenylhydantoininduced Pure Red Cell Aplasia. Blood, 65, 789-794. [Google Scholar] [CrossRef] 
[18] Mariette, X., Mitjavila, M.T., Moulinie, J.P., et al. (1989) Ri-fampicin-Induced Pure Red Cell Aplasia. The American Journal of Medicine, 87, 459-460. [Google Scholar] [CrossRef] 
[19] Bennett, C.L., Luminari, S., Nissenson, A.R., et al. (2004) Pure Red-Cell Aplasia and Epoetin Therapy. The New England Journal of Medicine, 351, 1403-1408. [Google Scholar] [CrossRef] 
[20] Choudry, M.A., Moffett, B.K. and Laber, D.A. (2007) Pure Red-Cell Aplasia Secondary to Pregnancy, Characterization of a Syndrome. Annals of Hematology, 86, 233-237. [Google Scholar] [CrossRef] [PubMed]
[21] Gurnari, C. and Maciejewski, J.P. (2021) How I Manage Ac-quired Pure Red Cell Aplasia in Adults. Blood, 137, 2001-2009. [Google Scholar] [CrossRef] [PubMed]
[22] Dessypris, E.N. (1988) Pure Red Cell Aplasia. Johns Hopkins University Press, Baltimore, 1-156.
[23] Au, W.Y., Cheng, V.C., Wan, T.S. and Ma, S.K. (2004) Myelodysplasia Masquerading as Parvovirus-Related Red Cell Aplasia with Giant Pronormoblasts. Annals of Hematology, 83, 670-671. [Google Scholar] [CrossRef] [PubMed]
[24] Thompson, C.A. and Steensma, D.P. (2006) Pure Red Cell Apla-sia Associated with Thymoma: Clinical Insights from a 50-Year Single-Institution Experience. British Journal of Hae-matology, 135, 405-407. [Google Scholar] [CrossRef] [PubMed]
[25] Balasubramanian, S.K., Sadaps, M., Thota, S., et al. (2018) Rational Management Approach to Pure Red Cell Aplasia. Haematologica, 103, 221-230. [Google Scholar] [CrossRef] [PubMed]
[26] Crabol, Y., Terrier, B., Rozenberg, F., et al. (2013) Intravenous Immunoglobulin Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection: A Retrospective Study of 10 Patients and Review of the Literature. Clinical Infectious Diseases, 56, 968-977. [Google Scholar] [CrossRef] [PubMed]
[27] Wu, X., Yang, Y., Lu, X., et al. (2019) Induced Complete Remission Faster in Adult Patients with Acquired Pure Red Cell Aplasia by Combining Cyclosporine A with Corticosteroids. Medi-cine (Baltimore), 98, e17425. [Google Scholar] [CrossRef] 
[28] D’Arena, G., Vigliotti, M.L., Dell’Olio, M., et al. (2009) Rituximab to Treat Chronic Lymphoproliferative Disorder-Associated Pure Red Cell Aplasia. European Journal of Haematology, 82, 235-239. [Google Scholar] [CrossRef] [PubMed]
[29] Au, W.Y., Lam, C.C., Chim, C.S., Pang, A.W. and Kwong, Y.L. (2005) Alemtuzumab Induced Complete Remission of Therapy-Resistant Pure Red Cell Aplasia. Leukemia Research, 29, 1213-1215. [Google Scholar] [CrossRef] [PubMed]
[30] D’Arena, G. and Cascavilla, N. (2009) Chronic Lymphocytic Leukemia-Associated Pure Red Cell Aplasia. International Journal of Immunopathology and Pharmacology, 22, 279-286. [Google Scholar] [CrossRef] [PubMed]
[31] Elimelakh, M., Dayton, V., Park, K.S., et al. (2007) Red Cell Aplasia and Autoimmune Hemolytic Anemia Following Immunosuppression with Alemtuzumab, Mycopheno-late, and Daclizumab in Pancreas Transplant Recipients. Haematologica, 92, 1029-1036. [Google Scholar] [CrossRef] [PubMed]
[32] Zhang, L., Chen, N., Xu, Z., et al. (2021) Good Treatment-Free Sur-vival of Monoclonal Gammopathy of Undetermined Significance Associated Pure Red Cell Aplasia after Bortezomib plus Dexamethasone. Blood Cells, Molecules, and Diseases, 89, Article ID: 102573. [Google Scholar] [CrossRef] [PubMed]
[33] Halkes, C., De, Wreede, L.C., Knol, C., et al. (2019) Allogeneic Stem Cell Transplantation for Acquired Pure Red Cell Aplasia. American Journal of Hematology, 94, E294-E296. [Google Scholar] [CrossRef] [PubMed]
[34] Huang, Y., Chen, M., Yang, C., Ruan, J., Wang, S. and Han, B. (2022) Si-rolimus Is Effective for Refractory/Relapsed/ Intolerant Acquired Pure Red Cell Aplasia: Results of a Prospective Sin-gle-Institutional Trial. Leukemia, 36, 1351-1360. [Google Scholar] [CrossRef] [PubMed]
[35] Chen, Z., Liu, X., Chen, M., Yang, C. and Han, B. (2020) Suc-cessful Sirolimus Treatment of Patients with Pure Red Cell Aplasia Complicated with Renal Insufficiency. Annals of Hematology, 99, 737-741. [Google Scholar] [CrossRef] [PubMed]
[36] Worel, N. (2016) ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation. Transfusion Medicine and Hemotherapy, 43, 3-12. [Google Scholar] [CrossRef] [PubMed]
[37] Aung, F.M., Lichtiger, B., Bassett, R., et al. (2013) Incidence and Natural History of Pure Red Cell Aplasia in Major ABO-Mismatched Haematopoietic Cell Transplantation. British Journal of Haematology, 160, 798-805. [Google Scholar] [CrossRef] [PubMed]
[38] Martino, R., García-Cadenas, I. and Esquirol, A. (2022) Daratumumab May Be the Most Effective Treatment for Post-Engraftment Pure Red Cell Aplasia Due to Persistent Anti-Donor Isohemag-glutinins after Major ABO-Mismatched Allogeneic Transplantation. Bone Marrow Transplantation, 57, 282-285. [Google Scholar] [CrossRef] [PubMed]
[39] Poon, L.M. and Koh, L.P. (2012) Successful Treatment of Iso-hemagglutinin-Mediated Pure Red Cell Aplasia after ABO-Mismatched Allogeneic Hematopoietic Cell Transplant Using Bortezomib. Bone Marrow Transplantation, 47, 870-871. [Google Scholar] [CrossRef] [PubMed]
[40] Means, R.T. (2022) Update on Pure Red Cell Aplasia: Etiology, Diagnosis, and Treatment. Clinical Advances in Hematology & On-cology, 20, 18-21.
[41] Nakazawa, H., Sakai, K., Ohta, A., et al. (2022) Incidence of Acquired Pure Red Cell Aplasia: A Nationwide Epidemiologic Analysis with 2 Registry Databases in Japan. Blood Advances, 6, 6282-6290. [Google Scholar] [CrossRef] [PubMed]

为你推荐